“Investigators analyzed data from 10 clinical trials of patients with Alzheimer disease who received cholinesterase inhibitors or memantine. Patients with Alzheimer disease (AD) who receive cholinesterase inhibitors (ChEIs) or memantine in clinical trials experience greater cognitive decline than patients who receive neither medication, according to study results published in JAMA Network Open.”
Read the full story at neurologyadvisor.com
Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer’s | Neurology Advisor
More from ResearchMore posts in Research »
- A possible blood test for early-stage Alzheimer’s disease | Medical Xpress
- Blood Biomarkers Plus Gene Status Predict Cognitive Decline : Neurology Today
- Early Detection of Alzheimer’s Prior to Onset of Symptoms Now Possible | Science Times
- We Need New Ideas for Fighting Alzheimer’s | Scientific American
- Immune view offers clues to early Alzheimer’s